Alimasi Kashafali

Alimasi Kashafali

Auto-generated profile, based on publicly available information

Alimasi Kashafali

Department of Research, Medical Research Circle (MedReC), Goma, DR Congo

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
CTChristian Tague
Christian Tague
DMDujardin Makeda
Dujardin Makeda
HYHermann Yokolo
Hermann Yokolo
JEJoshua Ekouo
Joshua Ekouo
LNLéopoldine Sybile Tatsadjieu Ngoune
Léopoldine Sybile Tatsadjieu Ngoune
AAAymar Akilimali
Aymar Akilimali
Endocrine disruptors (EDs) are a heterogeneous group of natural or synthetic chemicals capable of interfering with hormonal regulation. Widely present in plastics, cosmetics, pesticides, food packaging, and household products, they contribute to constant human exposure. Compounds such as bisphenol A, phthalates, parabens, dioxins, and certain pesticides are among the most studied. Their mechanisms of action include interaction with hormone receptors, modulation of gene expression through epigenetic changes, disruption of steroidogenesis, and interference with the hypothalamic–pituitary–gonadal axis. Evidence from animal and human studies suggests that EDs may reduce ovarian reserve, impair oocyte maturation, alter ovulation and implantation, and contribute to infertility. Associations have also been observed with polycystic ovary syndrome, endometriosis, and poorer outcomes of assisted reproductive techniques. Despite these findings, human data remain largely observational, with methodological limitations such as variable exposure assessment, lack of standardized biomarkers, and the unaddressed “cocktail effect.” Strengthening preventive strategies, regulatory measures, and further research is essential to better understand and mitigate the risks EDs pose to female reproductive health.

30 October 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
CTChristian Tague
Christian Tague
JEJoshua Ekouo
Joshua Ekouo
DMDujardin Makeda
Dujardin Makeda
HYHermann Yokolo
Hermann Yokolo
JOJones Onesime
Jones Onesime
AAAymar Akilimali
Aymar Akilimali
Therapeutic cancer vaccines represent a promising immunotherapy approach aimed at treating existing cancers by stimulating the patient’s immune system to target tumor cells. Unlike prophylactic vaccines, therapeutic vaccines are administered after cancer diagnosis and focus on inducing specific cytotoxic CD8 + T cell responses against tumor-associated antigens or tumor-specific neoantigens. These antigens are presented by antigen-presenting cells, such as dendritic cells, to activate an immune attack. However, the efficacy of therapeutic vaccines is often limited by immune tolerance, tumor heterogeneity, and an immunosuppressive tumor microenvironment, necessitating combination with other treatments like immune checkpoint inhibitors or chemotherapy. Multiple vaccine platforms are under investigation, including peptide/protein-based, DNA/messenger RNA (mRNA)-based, dendritic cell vaccines, viral vector vaccines, and personalized neoantigen vaccines that leverage next-generation sequencing for precision targeting. Clinical trials target a range of cancers, including melanoma, gynecologic, breast, pancreatic, liver, glioblastoma, and lung cancers, with results showing immune activation but modest clinical efficacy. Key challenges include immune evasion, variability in patient response, manufacturing complexities, high cost, and lack of predictive biomarkers. Technological advances in nanoparticle delivery, potent adjuvants, mRNA platforms, and combination immunotherapies are being explored to enhance vaccine performance. In low-resource settings, barriers such as limited access to advanced diagnostics and clinical trials necessitate tailored strategies to ensure equitable vaccine deployment. Overall, therapeutic cancer vaccines hold potential to become integrated into standard oncology protocols, especially for adjuvant therapy and recurrence prevention, with an emphasis on personalized and accessible immunotherapies to transform cancer management globally.

9 October 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
CTChristian Tague
Christian Tague
JEJoshua Ekouo
Joshua Ekouo
DMDujardin Makeda
Dujardin Makeda
HYHermann Yokolo
Hermann Yokolo
JOJones Onesime
Jones Onesime
AAAymar Akilimali
Aymar Akilimali
Marburg virus (MARV), a close relative of the Ebola virus, causes severe hemorrhagic fevers with a case fatality rate of up to 88%. In the absence of specific treatment or vaccine, its rapid spread through epidemics in Africa, particularly in Angola, DRC, Guinea, Uganda, and recently Tanzania, poses a major threat to global public health. The use of post-exposure prevention, already effective against viruses such as HIV and rabies, could offer a promising strategy to interrupt infection in recently exposed individuals. Remdesivir, a nucleotide analog initially developed against the Ebola virus and used for SARS-CoV-2, has shown significant antiviral activity against MARV in animal models. Administered within 24–48 hours of exposure, it reduces viral load and improves survival. This asymptomatic but active window of viral replication provides a valuable opportunity for intervention. Although clinical results are still lacking, preclinical data support urgent consideration of remdesivir as a rapid response tool. However, its logistical constraints (injectable form) limit its deployment in remote areas. Nevertheless, its integration into emergency protocols, accompanied by investments in research, early authorizations, and strategic stockpiles, could strengthen response capacities. While awaiting a vaccine, each antiviral option deserves rigorous attention to limit transmission and mortality during future Marburg outbreaks.

11 August 2026 in Public Health Challenges
Verified
Journal Article
Open access
PDF file
AKAlimasi Kashafali
Alimasi Kashafali
AAAbel Aizeque
Abel Aizeque
ZSZubayer Shams
Zubayer Shams
KFKanza Farhan
Kanza Farhan
Amidu AlhassanAmidu Alhassan
Amidu Alhassan
MCMedical Research Circle (MedReC) Collaborators
Medical Research Circle (MedReC) Collaborators
Introduction: Giving only breast milk in the first 6 months lowers the chances of childhood diseases and death. Still, it is difficult to promote ideal breastfeeding among internally displaced persons (IDPs) in camps. This research is intended to find out how many mothers are feeding their children under five with only breast milk in IDPs camps in Goma, eastern Democratic Republic of Congo (DRC). Methods: Between November 2024 and February 2025, an analytical cross‐sectional study was conducted in five major IDPs camps in Goma. A total of 407 eligible mothers or primary caregivers were recruited and participated in the study using a structured and pre‐tested questionnaire. Data were collected on sociodemographic characteristics, including maternal age, place of residence, and infant feeding practices. The chi‐square ( χ 2 ) test was employed to assess associations between exclusive breastfeeding (EBF) and selected explanatory variables, with statistical significance determined at p < 0.05. Results: The prevalence of EBF was 20.9%. Significant associations were observed between EBF and maternal age ( χ 2 = 18.8 and p < 0.05), educational level ( p < 0.05), marital status ( p < 0.05), presence of both parents ( p < 0.05), prematurity status ( χ 2 = 7.64 and p = 0.022), and source of household income ( χ 2 = 28.3 and p < 0.001). Higher EBF rates were reported among younger mothers, those with higher education, married women, and households receiving humanitarian aid (51.6%) compared to those relying on trade (16.2%). No significant associations were found between EBF and child's sex ( χ 2 = 0.177 and p = 0.674), camp of residence ( χ 2 = 0.688 and p = 0.953), or household size ( χ 2 = 3.78 and p = 0.052). Conclusion: IDPs camps demonstrate markedly low levels of exclusive breastfeeding, highlighting significant disparities between displaced populations and the general population. These findings underscore the need for targeted, context‐specific interventions, including strengthened maternal education, increased paternal support, and enhanced breastfeeding support programs, to improve infant health outcomes in humanitarian and crisis settings.

2 July 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
CTChristian Tague
Christian Tague
HYHermann Yokolo
Hermann Yokolo
JEJoshua Ekouo
Joshua Ekouo
DMDujardin Makeda
Dujardin Makeda
NATHAN MUGENYINATHAN MUGENYI
NATHAN MUGENYI
AAAymar Akilimali
Aymar Akilimali
An abstract is unavailable. This article is available as a PDF only.